Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, today announced the opening of its new environmentally friendly corporate headquarters in Philadelphia’s Navy Yard Corporate Center. This milestone is part of the Company’s long-term growth plan as it advances its late-stage pipeline of lower dose submicron non-steroidal anti-inflammatory drugs (NSAIDs) towards commercialization.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58559-iroko-pharmaceuticals-opens-philadelphia-headquarters-hq
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Boehringer Ingelheim Pharmaceuticals, Inc. y la Comisión Latina sobre el SIDA anunciaron hoy el lanzamiento del sitio web Mente, Cuerpo, HAART™ (MenteCuerpoHAART.com), un recurso en línea en español para los latinos que viven con el VIH, para proveedores de servicios de salud y para educadores de la salud. El sitio ofrece herramientas y consejos útiles sobre cómo mantener el bienestar mental, físico y emocional ante los desafíos diarios de la enfermedad.
Para ver más comunicado de prensa multimedios, visite http://multivu.prnewswire.com/mnr/boehringeringelheim/46494/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Takeda today announced the launch of a new expert Report on COPD, introduced at a Takeda organised press conference on the occasion of the 2012 European Respiratory Society (ERS) Annual Congress taking place from 1- 5 September in Vienna, Austria.
The Report, entitled ‘The Shifting Paradigm in Chronic Obstructive Pulmonary Disease (COPD) Management,’ was initiated and developed by Takeda Pharmaceuticals International GmbH and is a compilation of opinion articles from a panel of key international respiratory experts, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) and COPD patients, reflecting updated guidance and research. The new expert Report was developed in response to a recent shift in emphasis in COPD management which now places future risk at equal importance to treatment of current disability. Treatment objectives are now divided into two groups: reducing symptoms and reducing risk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56582-expert-report-on-copd-launch
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the initiation of production of The PBA Film Project (working title), the first-ever documentary to provide an intimate look at real people living with a little-known neurologic condition called PseudoBulbar Affect (PBA). The award-winning filmmaker team of The PBA Film Project includes co-directors Doug Blush and Lisa Klein (Of Two Minds) and producer Julian Cautherley (The Crash Reel).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7266955-avanir-pharmaceuticals-pseudobulbar-affect-pba-documentary/
Following years of trying to expand their family, Lisa and James Park of Raleigh, NC were named the winning family in Ferring Pharmaceuticals’ 2014 Heart to Heart Video Contest. This marks the tenth year Ferring has provided educational grants through patient contests, giving parents who have struggled with infertility the chance to win thousands of dollars for their child’s education by sharing their story.
Lisa and James’ rollercoaster journey to parenthood included multiple rounds of in vitro fertilization (IVF), intrauterine insemination (IUI) and a frozen embryo transfer. They hope that by sharing their story and video, they can help raise awareness about infertility and provide hope for others facing similar struggles. You can view Park family’s full video at www.hearttoheartcontest.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7444651-ferring-pharmaceuticals-heart-to-heart/
The Epilepsy Foundation launched the “Talk About It!” public service announcement featuring actor Greg Grunberg to raise awareness and encourage open dialogue about epilepsy and seizures. Greg, best known for his roles on Heroes, Alias, and Felicity, has an adult son who lives with epilepsy, a condition that affects nearly 3 million Americans. The Epilepsy Foundation and Greg teamed up for this PSA, sponsored by Sunovion Pharmaceuticals Inc., to drive much needed conversation about epilepsy – bringing the condition out of the shadows and honoring a community that deserves better awareness and understanding. More information about the PSA and initiative can be found by visiting the Epilepsy Foundation at epilepsy.com.
Nationally-recognized and long-standing sports announcer Jerry Punch, M.D., is teaming up with Men’s Health Network and Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), to launch “Ask About the Curve,” a new educational campaign designed to raise awareness of Peyronie’s disease. Peyronie’s disease is a little-known men’s health condition that can occur during midlife or later. And, while the disease is physical in nature, the impact may also be psychological and could possibly hold men back from talking about it.
Peyronie’s disease, or “PD,” is a condition that can cause curvature of the penis that could be painful during arousal and intimacy. It can affect as many as one in 10 men worldwide, but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help. Together with Endo and Men’s Health Network, Dr. Punch is encouraging men who think they might have PD to face their challenge head on by starting the conversation with their doctor.
“As a sports commentator, I’ve witnessed thousands of men on the court, on the field and on the racetrack in their physical prime – cool, confident and thriving in the face of challenge. But, as a licensed physician, I’ve seen how this bravado can turn to embarrassment – even isolation – when that challenge becomes personal or intimate,” said Dr. Punch. “Often, men feel too awkward to talk about issues like Peyronie’s disease, even with a doctor. And while it may seem tough, it’s important that any man with PD see a doctor, and ask about the curve. Starting the conversation is the first step to getting help.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7752151-ask-about-the-curve-psa/
Four-time PGA TOUR winner Tim Herron is teaming up with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), Damon Adamany, MD, of The CORE Institute and the Facts on Hand campaign to educate adults about one of the more common hand conditions. The campaign is raising awareness of Dupuytren’s Contracture, a progressive, potentially disfiguring hand condition affecting a layer of tissue underneath the palms that can cause one or more fingers to move into a bent position so they cannot be straightened.
Dupuytren’s Contracture, sometimes referred to as “Viking Disease,” can make everyday tasks difficult, such as grabbing an object at home, or in Tim Herron’s case, a nine iron from his golf bag. Many people live with the disease without being diagnosed because they mistakenly assume they have arthritis or another hand condition. And because Dupuytren’s Contracture may progress slowly, people may not pay attention to it until they can no longer straighten their fingers, complicating everyday activities.
To view the multimedia release go to:
https://www.multivu.com/players/English/8153851-endo-facts-on-hand-dupuytrens-contracture/
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
ACG – the leading partner for pharmaceutical industry’s myriad requirements – is strengthening its product portfolio by launching several new machines at CPhI/P-MEC India, to be held during 2-4 December 2014, at Bombay Exhibition Centre, Mumbai.
P-MEC India, co-located with CPhI India, is one of the ‘must-attend’ events in the international pharmaceutical industry. With a booth that spreads over 1,000 sq. m., ACG will be displaying several new machines including the all-new ACG X.One Technology that reinvents the 12-bar safety features; Protab, a tablet press suited for small to medium batch sizes, and many more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391551-ACG-Launch-New-Machines-at-CPhI/
